Yoshida Y, Ichinoe T, Dodo M, Noukawa M, Maeda A, Oguma S, Tajima M, Yamamoto K, Okuma M
Department of Medicine, Faculty of Medicine, Kyoto University, Japan.
Int J Hematol. 1994 Jul;60(1):79-83.
Bone marrow transplantation is widely accepted as the first line therapy for patients with severe aplastic anemia. Patients with less severe forms of aplastic anemia are treated with immunosuppressive agents, hematopoietic growth factors or androgenic steroids. The use of rabbit anti-human thymocyte globulin allowed us to successfully transplant in a patient with a moderately severe form who once failed to respond to all conservative treatment including equine anti-human lymphocyte globulin. We propose that, given the availability of rabbit anti-human thymocyte globulin, marrow transplantation should be considered in non-severe aplastic anemia patients who are refractory to equine anti-human lymphocyte globulin.
骨髓移植被广泛认为是重型再生障碍性贫血患者的一线治疗方法。病情较轻的再生障碍性贫血患者则采用免疫抑制剂、造血生长因子或雄激素类固醇进行治疗。兔抗人胸腺细胞球蛋白的使用使我们能够成功地为一名中度重型患者进行移植，该患者曾对包括马抗人淋巴细胞球蛋白在内的所有保守治疗均无反应。我们建议，鉴于有兔抗人胸腺细胞球蛋白可供使用，对于对马抗人淋巴细胞球蛋白难治的非重型再生障碍性贫血患者，应考虑进行骨髓移植。
